HemoSonics’ Quantra Hemostasis System for Obstetric Procedures Wins Silver 2026 Edison Award

Key Takeaways

• First FDA‑cleared viscoelastic test for obstetric bleeding
• Results delivered in under 15 minutes at point of care
• Silver Edison Award highlights innovation in women’s health
• Aims to cut postpartum hemorrhage deaths and transfusion use
• Adoption expanding across leading U.S. hospitals

Pulse Analysis

Postpartum hemorrhage remains the leading cause of maternal death worldwide, accounting for roughly 70,000 fatalities each year and a disproportionate share of U.S. maternal mortality. Clinicians often rely on standard laboratory coagulation panels that can take an hour or more, delaying critical decisions during active bleeding. The urgency of rapid, accurate hemostatic assessment has driven a search for point‑of‑care technologies that can bridge the gap between diagnosis and intervention, especially in obstetric settings where minutes can determine outcomes.

The Quantra Hemostasis System distinguishes itself by applying SEER Sonorheometry—a proprietary ultrasound‑based method—to whole‑blood samples, generating a comprehensive viscoelastic profile in less than 15 minutes. Unlike traditional thromboelastography, Quantra’s cartridge‑based design simplifies workflow, reduces operator dependence, and delivers actionable metrics such as clot stiffness and fibrin contribution. FDA 510(k) clearance for obstetric use in August 2025 confirms the device meets rigorous safety and efficacy standards, positioning it as a viable alternative to central lab testing and enabling clinicians to tailor blood‑product administration, minimize unnecessary transfusions, and improve hemostatic control during cesarean sections and vaginal deliveries.

Recognition by the Edison Awards amplifies the system’s market credibility and signals broader industry acceptance. As leading hospitals integrate Quantra into obstetric suites, the potential cost savings from reduced blood product usage and shorter intensive‑care stays become compelling for health systems facing tightening budgets. Moreover, the technology’s scalability suggests future extensions into other high‑bleed specialties, reinforcing HemoSonics' role in acute bleeding management. Continued adoption could catalyze a shift toward data‑driven, point‑of‑care hemostasis, ultimately lowering maternal mortality rates and setting new standards for peri‑operative care.